Reinhart Partners LLC. Sells 11,822 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Reinhart Partners LLC. cut its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 18.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 50,676 shares of the medical research company's stock after selling 11,822 shares during the quarter. Reinhart Partners LLC. owned 0.10% of Charles River Laboratories International worth $9,355,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Virtu Financial LLC bought a new position in shares of Charles River Laboratories International during the 3rd quarter worth about $601,000. JPMorgan Chase & Co. increased its stake in shares of Charles River Laboratories International by 21.6% in the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company's stock worth $95,086,000 after purchasing an additional 85,759 shares in the last quarter. State Street Corp raised its holdings in Charles River Laboratories International by 2.0% during the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company's stock valued at $419,601,000 after acquiring an additional 41,421 shares during the period. Janus Henderson Group PLC grew its stake in Charles River Laboratories International by 7.6% during the third quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company's stock valued at $9,064,000 after acquiring an additional 3,268 shares in the last quarter. Finally, Neo Ivy Capital Management bought a new stake in Charles River Laboratories International during the third quarter valued at $966,000. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Charles River Laboratories International

In other news, Director Richard F. Wallman sold 6,621 shares of the company's stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the sale, the director now directly owns 12,386 shares in the company, valued at approximately $2,676,862.32. This represents a 34.83 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Price Performance

Shares of Charles River Laboratories International stock traded up $4.01 on Monday, hitting $190.13. 670,633 shares of the company traded hands, compared to its average volume of 632,662. Charles River Laboratories International, Inc. has a 52 week low of $176.48 and a 52 week high of $275.00. The business has a 50-day simple moving average of $193.57 and a 200 day simple moving average of $199.32. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. The stock has a market capitalization of $9.72 billion, a P/E ratio of 23.80, a price-to-earnings-growth ratio of 5.00 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $975.99 million. During the same period in the previous year, the firm posted $2.72 EPS. Charles River Laboratories International's revenue for the quarter was down 1.6% compared to the same quarter last year. Research analysts expect that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Redburn Atlantic started coverage on shares of Charles River Laboratories International in a research report on Monday, October 14th. They set a "sell" rating and a $151.00 price objective on the stock. TD Cowen raised their target price on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a "hold" rating in a research report on Monday, November 11th. Citigroup downgraded Charles River Laboratories International from a "neutral" rating to a "sell" rating and decreased their price objective for the stock from $215.00 to $175.00 in a report on Tuesday, October 1st. Evercore ISI upped their price target on Charles River Laboratories International from $190.00 to $225.00 and gave the stock an "in-line" rating in a research note on Thursday, November 7th. Finally, UBS Group increased their price objective on Charles River Laboratories International from $240.00 to $250.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. Three investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $214.00.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).